Intellia Therapeutics (NTLA) Proxy filing summary

Executive summary

• The annual meeting will be held virtually on June 9, 2026, with voting on three director nominees, auditor ratification, and a say-on-pay proposal.

• The board recommends voting for all proposals and highlights the use of internet-based proxy materials to reduce costs and environmental impact.

• Forward-looking statements address clinical trial progress and anticipated product launches, with risks noted regarding regulatory and operational uncertainties.

Voting matters and shareholder proposals

• Shareholders will vote on electing three class I directors for three-year terms, ratifying Deloitte & Touche LLP as auditor for 2026, and approving executive compensation on an advisory basis.

• The board unanimously recommends voting for all proposals.

• Shareholders may submit proposals for the 2027 meeting by December 31, 2026, and can recommend director candidates.

Board of directors and corporate governance

• The board consists of eight members divided into three staggered classes, with detailed biographies and qualifications provided for each director.

• All directors except the CEO are considered independent under Nasdaq and SEC rules.

• The board has audit, compensation, nominating and corporate governance, and science and technology committees, each with defined responsibilities and independent members.

• Stock ownership guidelines require directors and executives to hold equity equal to at least three times their annual retainer or base salary.

• The company prohibits short sales, hedging, and unauthorized pledging of company stock.